ACCRIVA DIAGNOSTICS HEMOCHRON SIGNATURE ELITE INTERNATIONAL; SYSTEM, MULTIPURPOSE FOR IN VITRO COAGULATION STUDIES
|
Back to Search Results |
|
Model Number ELITE-INT |
Device Problem
Non Reproducible Results (4029)
|
Patient Problem
No Known Impact Or Consequence To Patient (2692)
|
Event Date 03/09/2018 |
Event Type
malfunction
|
Manufacturer Narrative
|
This mdr references accriva diagnostics' complaint number (b)(4) for the hemochron signature elite international instrument, serial number (b)(4).Accriva diagnostics' complaint number (b)(4) referenced the child case capturing the disposable hemochron jr.Act-lr device (lot number j7jlr194) that was used during the procedure.Method: testing of actual/suspected device.Dhr review showed no ncs, capa, or a relevant history of repair.Results: no device problem found.The instrument was tested to heparin sensitivty procedure qc-188 using 2 lots of act-lr cuvettes and side by side with 3 other control instruments.The device performed within specifications.Conclusion: no problem detected.This mdr serves as the initial and final report for the hemochron signature elite and act-lr microcoagulation system, instrument serial number (b)(4), lot j7jlr194.The complaint was not confirmed.
|
|
Event Description
|
Healthcare professional working in a hospital in (b)(6) reported that two hemochron signature elite and act low-range assay systems reported inconsistent act results when the meters were run side-to-side during a pci and stent placement procedure.The patient was receiving intermittent doses of intravenous heparin with a target act range of 300-350 seconds.The same lot number of hemochron jr act-lr cuvettes (j7jlr194) was used on both meters throughout the procedure.One blood sample generated a pair of act results that differed significantly from one another.The act result assayed on the elite named in this complaint ((b)(4)) was 254 seconds, which was lower than the target act.The act result reported on the second elite ((b)(4)) was 321 seconds, which was an expected result.The act result of 321 seconds was used for patient management.No bleeding, thrombosis or other medical complications were reported.Both hemochron signature elite instruments passed electronic qc before the procedure.Act-lr readings with liquid qc (normal and abnormal levels) were within their acceptable ranges when run on both instruments.The distributor asked the customer to return the device for evaluation, however, the customer declined to do so as of (b)(6) 2018, when accriva closed the initial complaint.The complaint case was reopened on (b)(6) 2018 when the customer decided to return the instrument to accriva for evaluation because of recurrent instances of reporting inconsistent act results.
|
|
Search Alerts/Recalls
|
|
|